Strong Financial Performance: Research Reports on Intersect ENT, Emulex, SYNNEX, Wayfair, and Pharmacyclics

NEW YORK, January 14, 2015 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Intersect ENT (NASDAQ: XENT), Emulex (NYSE: ELX), SYNNEX (NYSE: SNX), Wayfair (NYSE: W), and Pharmacyclics (NASDAQ: PCYC). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

XENT Research Report: ( http://get.analystsreview.com/pdf/?c=Intersect%20ENT&d=14-Jan-2015&s=XENT ),

ELX Research Report: ( http://get.analystsreview.com/pdf/?c=Emulex&d=14-Jan-2015&s=ELX ),

SNXResearch Report: ( http://get.analystsreview.com/pdf/?c=SYNNEX&d=14-Jan-2015&s=SNX ),

WResearch Report: ( http://get.analystsreview.com/pdf/?c=Wayfair&d=14-Jan-2015&s=W ),

PCYC Research Report: ( http://get.analystsreview.com/pdf/?c=Pharmacyclics&d=14-Jan-2015&s=PCYC ).

============

--

Analyst Update: Preliminary Earnings Releases and Holiday Sales Numbers

Reviewed by: Rohit Tuli, CFA®  

Volatility gripped the U.S. market on Tuesday as the Dow Jones Industrial Average, which vaulted over 282 points during the session, erased all the gains and slipped into negative territory, led by a decline in materials and energy shares. The U.S. stocks fluctuated between gains and losses during the session, mirroring the movement in oil prices which tumbled to near six-year lows before recovering. The Dow Jones Industrial Average ended the session 0.15% lower at 17,613.68, the S&P 500 lost 0.26% to close at 2,023.03, and the Nasdaq Composite dropped 0.07% to 4,661.50. Meanwhile, European shares rose for the second consecutive session on Tuesday, helped by rally in retail stocks and data showing that U.K. inflation fell to the lowest level in 15 years. Most of the Asian markets also ended lower on Tuesday as continued drop in the prices of oil turned investors cautious towards risky assets.

Shares of Intersect ENT Inc. (Intersect ENT) went through the roof, after the Company presented a snapshot of its Q4 2014 and full year 2014 financial results. The stock gained over 22% in trade to end the trading session at $23.04. Read more about the preliminary financial results and the latest developments concerning Company's PROPEL and PROPEL mini - world's first and only drug-releasing sinus implants, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis.

Emulex Corporation's (Emulex) stock hit escape velocity, after the Company announced upbeat preliminary Q2 FY 2015 financial results. The Company will host a conference call on January 29, 2015 2:00 p.m. PDT to discuss the financial results in detail. A further detailed analysis of the preliminary financial results is available in our research report on Emulex.

Shares of SYNNEX Corporation (SYNNEX) rallied almost 10% after the Company reported record revenue and income for Q4 FY2014 and full year FY 2014. Also, the Company announced quarterly cash dividend of $0.125 per common share payable on January 30, 2015 to the shareholders of record as of the close of business on January 16, 2015. To know more about the financial results and Q1 FY2015 financial guidance, read our report on SYNNEX.

Investors appear to be pleased with Wayfair Inc (Wayfair) holiday sales numbers, which increased 51% in overall gross sales, and a 76% increase in Direct Retail gross sales for the five-day peak shopping period of Thanksgiving Day through Cyber Monday. Read in detail about the holiday sales numbers and the management's viewpoint in our research report on Wayfair.

Shares of Pharmacyclics, Inc. (Pharmacyclics) skyrocketed 16% to end the trading session at $144.0, after the Company announced its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Read more about financial results and 2015 outlook in our research report on Pharmacyclics.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED